Effect of Zoledronic acid for Stage D2 hormone-sensitive prostate cancer patients.
Phase 2
- Conditions
- Prostate Cancer
- Registration Number
- JPRN-UMIN000002577
- Lead Sponsor
- Department of Urology, Keio University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Male
- Target Recruitment
- 96
Inclusion Criteria
Not provided
Exclusion Criteria
1.CCr < 30mL/min by calculation of Codkcroft Gault equation. 2. Another cancer that requires treatment 3. Patients coexisting psychiatric disease or neurological symptom 4. Patients with continuous systematic treatment with steroids 5. Participation in the present study is considered inappropriate by a Clinical Investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1 PSA nadir rate 2 Time to PSA nadir
- Secondary Outcome Measures
Name Time Method 1 Refractory Free Survival 2 Safety